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Abstract
This communication reports a new theranostic system with a combination of capabilities to both
enhance the contrast of photoacoustic (PA) imaging and control the release of a chemical or
biological effecter by high-intensity focused ultrasound (HIFU). The fabrication of this system
simply involves filling the hollow interiors of gold nanocages with a phase-change material
(PCM) such as 1-tetradecanol that has a melting point of 38–39 °C. The PCM can be pre-mixed
and thus loaded with a dye, as well as other chemical or biological effecters. When exposed to
direct heating or HIFU, the PCM will melt and escape from the interiors of nanocages through
small pores on the surface, concurrently releasing the encapsulated molecules into the surrounding
medium. We can control the release profile by varying the power of HIFU, the duration of
exposure to HIFU, or both.
Hollow nanostructures have been extensively explored as drug delivery systems for
biomedical applications due to their unique capability to hold and release drugs.1 Most of
these structures are composed of lipids, including liposomes (uni- and multi-lamella
vesicles) and multi-channeled cubo- or hexosomes.2 Polymeric nanoparticles with various
compositions, structures, and porosities have also been investigated for similar applications.3
Typically, the interiors of these hollow nanostructures are loaded with drugs (hydrophilic or
hydrophobic) in different formulations that are able to escape via diffusion or degradation-
triggered release. In addition, the release can be triggered and regulated in response to
environmental changes such as pH and temperature. Recently, inorganic and composite
hollow nanostructures have also received attention for drug delivery applications. A number
of groups have reported delivery systems based on mesoporous silica particles containing
water-insoluble drugs,4 and metal-organic framework (MOF) particles incorporated with
drugs.5 Although the inclusion of inorganic components such as metal ions may cause
potential toxicity issues, it offers advantages such as multi-functionality, a feature required
for future theranostic applications. For example, the metal ions can serve as contrast agents
for magnetic resonance imaging (MRI), adding a unique capability to resolve and track the
in vivo location of a drug delivery system.6
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Hollow nanostructures of noble metals, such as Au nanocages (AuNCs), represent another
attractive platform for theranostic applications. Thanks to their strong, highly tunable
scattering and absorption in the near-infrared (NIR) from 700–900 nm, AuNCs are
wonderful contrast agents for a variety of imaging modalities including photoacoustic
tomography (PAT) and optical coherence tomography (OCT).7 They have also been used to
control the release of hydrophilic drugs with NIR laser or HIFU by coating their surfaces
with smart polymers.8 While the NIR laser-triggered release has to rely on the photothermal
effect of AuNCs, HIFU can directly deposit acoustic energy in the focal volume to rapidly
raise the temperature.8b The availability of AuNCs loaded with therapeutic drugs offers a
great benefit to theranostic applications because the AuNCs can be monitored with an
optical imaging technique while the drug is released at the targeted site in a controllable
fashion. As expected, the released drug can also greatly enhance the efficacy of
photothermal cancer treatment, which has been demonstrated with success in the absence of
an anticancer drug.9 While the system based on AuNCs and smart polymers has been
successfully used for controlled release under the irradiation of NIR laser or HIFU, the
loaded drugs can escape from the hollow interiors of AuNCs through a slow diffusion
process in the absence of any thermal stimulus. In addition, this system only works for
hydrophilic drugs because the as-prepared nanocages are typically coated with a hydrophilic
polymer such as poly(vinyl pyrrolidone), making it difficult for a hydrophobic species to
diffuse into the hydrophilic interior of a AuNC. Since more than 40% of the active
compounds identified by the combinatorial screening programs are poorly soluble in
water,11 finding a system well-suited for encapsulation of both hydrophilic and hydrophobic
drugs is expected to greatly extend their scope of use in theranostic applications. In addition
to the features needed for imaging purpose, the new system should show negligible release
until it is triggered by an external stimulus.
Herein, we present a facile and versatile strategy for loading either hydrophobic or
hydrophilic drugs into the hollow interiors of AuNCs. We use a phase-change material
(PCM) as the medium to help load the drug, which can also serve as a “gate-keeper” to
control the release of drug in response to temperature increase.11 In principle, the
encapsulated drug should not be released until the PCM has been melted due to heating by a
thermal, photothermal, or ultrasonic means. Figure 1A shows a schematic diagram of the
encapsulation and release mechanisms. Since a PCM reversibly changes its physical states
between solid and liquid over a narrow temperature range, it can perfectly confine drug
molecules inside the AuNCs at a temperature below its melting point (the solid state). When
the local temperature is raised beyond the melting point of the PCM, it will begin to melt
(the liquid state) and the drug will be released from the melted PCM through diffusion.
Taken together, this new system should allow one to regulate the release of a drug and the
profile by manipulating the temperature. As long as the drug is miscible with the PCM
phase, it can be conveniently loaded into the hollow interiors of AuNCs as the PCM diffuses
into the nanocages. This requirement can be readily met by choosing PCMs with the
surfactant-like behavior, such as those containing both long hydrophobic tails and
hydrophilic heads. In this work, we chose to focus on 1-tetradecanol, a fatty alcohol
characterized by attractive features such as immiscibility with water, good biocompatibility,
and a melting point (38–39 °C) slightly higher than the normal human body temperature
(37.0 °C). It can also be mixed with a range of hydrophilic and hydrophobic substances.
Furthermore, 1-tetradecanol is an ingredient widely used in cosmetics due to its low toxicity
(oral, rat LD50 >5 g/kg).12
The AuNCs used in this study were prepared by means of a galvanic replacement reaction
between Ag nanocubes (44 ± 6.7 nm in edge length) and HAuCl4 in an aqueous solution
under refluxing condition.13 The resultant AuNCs had an outer edge length of 60 ± 11 nm,
together with a wall thickness of 7.5 ± 2.8 nm. Essentially all of them contained at least one
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pores (~10 nm in size) on the surface (Fig. S1). The as-prepared nanocages were then re-
dispersed in methanol after repeated washing with deionized water and centrifugation 4
times. For encapsulation, we used Rhodamine 6G (R6G) and methylene blue (MB) as two
examples of drugs with different solubilities in water. As a major advantage over most real
drugs, the release of these two dyes can be easily monitored and quantified through the use
of UV-vis absorption spectroscopy.
In a typical experiment, the PCM was added to a glass vial and placed in an oil bath set to 90
°C to melt the PCM into a liquid, followed by the addition of a dye. After the dye and PCM
had been thoroughly mixed, we introduced the AuNCs as a suspension in methanol. Even
after the methanol had been evaporated due to stirring and heating, the AuNCs were still
well dispersed in the liquid PCM. During this process, the mixture of PCM and dye
molecules slowly entered the hollow interior of each nanocage by diffusion through the
pores on the surface. After the system had been continued with heating at 90 °C for 2 h, a
small amount of hot water was added to generate two separated phases, one being the PCM/
dye mixture and the other containing the loaded AuNCs and water, as a result of
immiscibility between the PCM and water. The AuNCs were preferentially extracted into
the water phase due to their hydrophilic surfaces. Interestingly, both PCM and dye
molecules inside the nanocages were effectively retained because it was difficult for the
PCM molecules to quickly diffuse into water due to their immiscibility. Finally, the AuNCs
encapsulated with the PCM/dye mixture were collected by centrifugation and then re-
dispersed in deionized water under brief sonication (for 10 sec). In the course of re-
dispersion, a very small portion of the encapsulated PCM/dye could escape from the AuNCs
owning to the heat generated by sonication (Fig. S2).
Figure 1, B and C, shows typical transmission electron microscopy (TEM) images of the
nanocages before and after loading of the PCM/dye mixture. Compared with the pristine
sample, nanocages loaded with the PCM/dye mixture showed a conspicuous difference in
contrast. It should be pointed out that the PCM-dye mixture inside the nanocage was often
smaller in volume than the actual void of the nanocage. To quantify the amount of PCM/dye
loaded inside the AuNCs, we obtained thermal gravimetric analysis (TGA) data in the range
of 50–500 °C (Fig. 1D). The TGA results show a weight loss of 3.4%, which is lower than
the loading of 4.0% calculated from the density of PCM and physical dimensions of the
nanocages (Supporting Information). This data suggests that, on average, only 84% of the
void space inside each AuNC was actually occupied by the PCM/dye mixture.
Figure 1E shows UV-vis absorption spectra recorded from aqueous suspensions of pristine
AuNCs, AuNCs containing the PCM, and AuNCs containing both PCM and the dye (R6G
or MB). It is worth pointing out that the AuNCs loaded with a PCM/dye mixture also
exhibited characteristic peak of the dye, confirming successful encapsulation of the dye
inside the AuNCs. The major localized surface plasmon resonance (LSPR) peak of the
nanocages was found to be broadened and slightly red-shifted, most likely caused by some
minor aggregation during sample preparation.
Figure 2 shows the release of R6G from the AuNCs by direct heating and HIFU heating,
respectively. As shown in Figure 2A, the amount of R6G released was negligible at room
temperature because the dye was entrapped by solid PCM inside the nanocages, which
makes it difficult for the dye molecules to diffuse into the surrounding medium. At 37 °C,
there was a slight increase in the release of R6G (still below 5% over a period of 3 days)
although the melting point of 1-tetradecanol (38–39 °C) was still slightly higher than this
temperature. In comparison, 28% of the encapsulated R6G was released from the AuNCs in
3 days when the sample was held at 40 °C. As an important feature, the PCM-based release
could be easily regulated by controlling the temperature. We confirmed this feature by
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investigating the release behaviors during repeated heating-cooling cycles at temperatures
below and above the melting point of 1-tetradecanol (Fig. 2B). Note that the release of dye
was only observed when the sample was heated to 40 °C and held for 2 h.
Due to its good compatibility with both hydrophobic and hydrophilic substances, we found
that the PCM could also be used as a matrix for the encapsulation and release of a drug more
soluble in water than R6G. We demonstrated this capability by switching to MB, a dye more
hydrophilic than R6G. In this case, we found that the loading capacity of MB was much
lower than that of R6G (57% vs. 84% for the MB and R6G, respectively, see Supporting
Information). As a result, the cumulative release of MB was three times higher than that of
R6G (Fig. 2C). Since MB was quickly photo-bleached (Fig. S3), the cumulative release
percentage corrected for bleaching showed that 80% of the loaded MB was released in 24 h
(Fig. S4). These results clearly demonstrate that the PCM works for chemical species with
different solubilities in water, making this new system a useful platform for a wide variety
of drugs.
Figure 2D shows the release profiles of R6G as a function of the power of HIFU. HIFU has
been used as a promising clinical technology for tumor treatment due to its deep penetration
and non-invasive nature.14 Most recently, we have also adapted this technique for triggering
the release of dye molecules from AuNCs whose surfaces were covered with smart polymer
brushes.8b As a major advantage over the smart polymers, the PCM-based system showed
better encapsulation efficacy and much lower background release (data not shown). In the
present work, we also found that the focused ultrasound wave could rapidly increase the
overall temperature of a suspension of AuNCs loaded with PCM and dye (Fig. S5). As
clearly shown in Figure 2D, the quick increase in temperature caused the R6G to release
from the hollow interiors of AuNCs. As expected, the release profile also displayed a strong
dependence on the power of HIFU, making it possible to control the release dosage on
demand.
In conclusion, we have demonstrated a nanoscale, temperature-regulated drug release
system by combining the unique features of AuNCs and PCMs. As a deeply penetrating
energy source, HIFU can be used to trigger the release and to control the release profile by
adjusting the duration of exposure and/or the power applied. The new hybrid system
described in this work can also be further developed into a theranostic system with an array
of functions, including the capabilities for in vivo molecular imaging, as well as chemo- and
photothermal therapy.
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Figure 1.
(A) Schematic illustrating how to load the hollow interior of a AuNC with a dye-doped
PCM and then have it released from the AuNC by direct or ultrasonic heating. (B, C)
Typical TEM images of a AuNC before and after its hollow interior had been loaded with a
mixture of 1-tetradecanol (the PCM) and R6G (the drug). The scale bars are 20 nm. (D)
TGA data of the pristine AuNCs (dotted) and the AuNCs containing PCM/R6G (solid). (E)
UV-Vis absorption spectra of the AuNCs before and after loading with the PCM/dye
mixtures.
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Figure 2.
Release profiles of (A) R6G under direct heating to various temperatures for different
periods of time, (B) R6G through different cycles of heating (40 °C, for 2 h) and cooling (to
room temperature), (C) R6G and MB by direct heating to 40 °C for different periods of time,
and (D) R6G by HIFU at different applied powers.
Moon et al. Page 7
J Am Chem Soc. Author manuscript; available in PMC 2012 April 6.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
